Over the last decade, public awareness of the mental health challenges women face has grown tremendously, and we can say with certainty that we have succeeded in putting this important topic firmly on the medical [...]
Several weeks ago, the US Preventive Services Task Force (USPSTF) issued recommendations that all pregnant and postpartum women should be evaluated in order to determine risk for depressive illness and suggests that women at increased [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
Postpartum depression (PPD) is a common and complicated illness, affecting about 15% of women in the perinatal period. Recent research from the PACT consortium (Postpartum Depression: Action Toward Causes and Treatment) has sought to classify [...]
January 30, 2019 from ObGynNews  The last decade has brought appropriate attention to the high prevalence of postpartum mood and anxiety disorders, with postpartum depression (PPD) constituting the most common complication in modern obstetrics. [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on preventing postpartum depression with Ob.Gyn News on January 30, 2019 The last decade [...]
In the earliest studies, postpartum depression was described an episode of depression associated with childbirth, typically emerging within the first three months after delivery. Â As more research has been carried out, we have learned [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
In a recent study from Quebec, researchers compared the risk of postpartum depression in more than 35,000 pregnant women with asthma and almost 200,000 women without asthma. Â They found that rates of postpartum depressive symptoms [...]
